Publication
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerBone Ewing Sarcomacivic_curation1.00
- cancerEwing Sarcomacivic_curation1.00
- drugCixutumumabcivic_curation1.00
- drugIGF1R Monoclonal Antibodycivic_curation1.00
- drugTemsirolimuscivic_curation1.00
- drugTeprotumumabcivic_curation1.00
- genePTPRDcivic_curation1.00
- variantPTPRD R995Ccivic_curation1.00
- variantPTPRD V253Icivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23800680
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PTPRD V253I1 | ||||||||
| Cixutumumab + TeprotumumabSubstitutes | Bone Ewing SarcomaALIAS | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1856Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C). The third patient had … (full text at CIViC) PMID 23800680 · Jiang et al., 2013 · Open in CIViC | civic |
| PTPRD R995C1 | ||||||||
| IGF1R Monoclonal Antibody + TemsirolimusCombination | Ewing Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID10061An analysis of 8 ewing sarcoma patients revealed PTPRD mutations in 3 cases (V253I/W775*, T781A, R995C). 2 of 3 cases showed complete response (RECIST criteria) to IGF1R mAb based therapies. The R995C… (full text at CIViC) PMID 23800680 · Jiang et al., 2013 · Open in CIViC | civic |
| PTPRD T781A1 | ||||||||
| IGF1R Monoclonal Antibody + TemsirolimusCombination | Ewing Sarcoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID10062An analysis of 8 ewing sarcoma patients revealed PTPRD mutations in 3 cases (V253I/W775*, T781A, R995C). 2 of 3 cases showed complete response (RECIST criteria) to IGF1R mAb based therapies. The thrid… (full text at CIViC) PMID 23800680 · Jiang et al., 2013 · Open in CIViC | civic |